Description
Cenforce-ld
Cenforce-ld is presented as a combination product containing sildenafil and dapoxetine. The supplied product name and strength details identify the medicine as a combined phosphodiesterase type 5 (PDE5) inhibitor and selective serotonin reuptake inhibitor (SSRI) formulation. Because branded products can vary by market, the active ingredients should be verified against the official product information for the exact item sold.
Active Ingredient and Medicine Class
Sildenafil is a PDE5 inhibitor. In official labeling, sildenafil is used for erectile dysfunction in many markets and is also marketed for pulmonary arterial hypertension in some formulations. Dapoxetine is a short-acting SSRI and is the first oral medicine specifically developed for premature ejaculation in adult men in jurisdictions where it is approved.
Established Medical Uses
The combination of sildenafil and dapoxetine has been studied for men who have both erectile dysfunction and premature ejaculation. Clinical studies have evaluated whether the two medicines together can improve erection-related outcomes and ejaculation timing in this group. Dapoxetine alone has established use for premature ejaculation, while sildenafil is an established treatment for erectile dysfunction.
How It Works
Sildenafil helps relax smooth muscle in the penis by inhibiting PDE5, which increases the effect of nitric oxide and supports blood flow during sexual stimulation. Dapoxetine increases serotonin signaling by inhibiting serotonin reuptake, which can delay ejaculation. The combination is intended to address two different mechanisms involved in sexual function.
Important Safety Information
Sildenafil is contraindicated with nitrates and with riociguat because of the risk of marked blood pressure lowering. Dapoxetine should not be used with several serotonergic and monoamine oxidase inhibitor medicines and is contraindicated in people with certain psychiatric, cardiac, liver, or bleeding-related risks in the official product information. Both ingredients can contribute to dizziness or blood pressure effects, and combined use may increase the importance of screening for interacting medicines and cardiovascular suitability.
Possible Side Effects
Reported adverse effects for sildenafil include headache, flushing, dizziness, nasal congestion, and visual disturbances; serious reactions can include severe hypotension, priapism, and cardiovascular events in susceptible patients. Dapoxetine is commonly associated with nausea, headache, dizziness, diarrhea, and insomnia; syncope and postural dizziness are important safety concerns. Combination studies have reported mostly mild to moderate adverse effects, but discontinuation can occur.
Scientific Evidence
Human studies suggest that dapoxetine/sildenafil combinations can improve intravaginal ejaculatory latency time and patient-reported outcomes in men with premature ejaculation plus erectile dysfunction. In a randomized placebo-controlled trial of dapoxetine with background PDE5 inhibitor use, dapoxetine improved latency time and global impression measures versus placebo. An open-label combination study also reported improved latency time and sexual function scores, with non-serious adverse events in a minority of participants.
Medical Information Notice
This educational summary is based on sources available at the time of review and does not replace the official patient leaflet, prescribing information, or individual assessment by a qualified healthcare professional.
Medical Sources
- DailyMed — SILDENAFIL tablet, film coated
- EMA — Priligy (dapoxetine) — Summary of Product Characteristics
- McMahon CG et al. “Efficacy and safety of dapoxetine in men with premature ejaculation and concomitant erectile dysfunction treated with a phosphodiesterase type 5 inhibitor: randomized, placebo-controlled, phase III study.” Journal of Sexual Medicine (2013). PubMed
- Tuken M et al. “Efficacy and safety of dapoxetine/sildenafil combination tablets in the treatment of men with premature ejaculation and concomitant erectile dysfunction-DAP-SPEED Study.” International Journal of Impotence Research (2019). PubMed
